Karyopharm Therapeutics Return on Equity

Karyopharm Therapeutics (KPTI) currently reports a ROE of 68.07%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Karyopharm Therapeutics's ROE history and peer comparisons.

Karyopharm Therapeutics's ROE of 68.07% is higher than the Healthcare sector average of 21.67%. That is roughly 214.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Karyopharm Therapeutics's current 68.07% should be judged against Healthcare norms (sector average: 21.67%) and against KPTI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 68.07%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Karyopharm Therapeutics, and consider following KPTI for alerts when major investors trade the stock.

Karyopharm Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 68.07% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KPTI with unrelated industries.